Arbutus Biopharma (ABUS) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 232.1% versus a gain of 0.0%. Nuvectis Pharma is the larger company by market cap ($662.3 million vs $657.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | NVCT |
|---|---|---|
| Share price | $4.29 | $20.29 |
| Market cap | $657.55M | $662.35M |
| 1-day change | -4.24% | +1.30% |
| YTD return | -10.81% | +168.74% |
| 1-year return | 0.00% | +232.08% |
| 5-year return | +5.15% | — |
| P/E ratio (TTM) | 5.64 | — |
| EPS (TTM) | $0.76 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $29.28 |
| 52-week low | $3.50 | $5.55 |
| Distance from 52-week high | -21.28% | -30.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +24.71% | +74.47% |
| Average volume | 4.68M | 219.45K |
| Shares outstanding | 153.28M | 32.64M |
| Employees | 19 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed ABUS by 232.1 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Healthcare · Biotechnology · 19 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
ABUS vs NVCT FAQ
Which is bigger, Arbutus Biopharma or Nuvectis Pharma?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $662.35M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or NVCT?
NVCT returned +232.08% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.